CEO: David Newns

Advent Contact: Kaasim Mahmood

First MHRA approved e-cigarette

CN Creative developed the Nicadex inhaler (now known as e-Voke) as a nicotine replacement therapy. The Nicadex device provides a safer alternative to cigarettes while still addressing smoker’s nicotine cravings. Nicadex was approved as a medical device by the MHRA in 2015.

Advent was the sole investor in the Series A in 2011. The Company was acquired by British American Tobacco in 2012.